Radiofrequency ablation for renal tumours: A retrospective study from a tertiary centre

doi:10.1016/j.ajur.2021.10.003

摘要
图/表
参考文献
相关文章
推荐阅读
Metrics

下载:

HTML

PDF (443KB)
输出: BibTeX | EndNote (RIS)

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	（）
	作者相关文章

Abstract:

Objective: This study aimed to evaluate the safety and efficacy outcomes of percutaneous radiofrequency ablation (RFA) for localised renal cell carcinoma (RCC) in a tertiary hospital patient who remained unfit for surgical intervention.
Methods: We retrospectively analysed survival outcomes for patients with biopsy proven RCC treated by RFA at Royal Perth Hospital between September 2009 and May 2018. Complication data were gathered for all patients that underwent renal RFA along with 2- and 5-year recurrence-free survival (RFS) rate and compared the outcomes with data from previous studies.
Results: A total of 69 patients (73 procedures) were eligible for the study, and those patients had biopsy-proven RCC with a minimum of 2-year follow-up. The complication rate was 8.2% (6/73) and local recurrence rate 9.6% (7/73). Two-year RFS is 95.7% and 5-year RFS is 78.8% on a median 3.82-year follow-up (interquartile range 1.90-5.75 years).
Conclusion: RFA performed at our centre was found to be safe and effective with low complication rates and durable RFS in line with expectations from existing research. Our study demonstrated that RFA is an alternative modality of treatment for small renal tumours in patients unfit for surgical approach.

Key words: Radiofrequency ablation Small renal tumour Hydrodissection Renal cell carcinoma

收稿日期: 2020-11-17 修回日期: 2021-04-05 接受日期: 2021-07-02 出版日期: 2023-04-20 发布日期: 2023-05-24 整期出版日期: 2023-04-20

引用本文:

. [J]. Asian Journal of Urology, 2023, 10(2): 177-181.
Mohammed Al-Zubaidi,Kennia Lotter,Martin Marshall,Mikhail Lozinskiy. Radiofrequency ablation for renal tumours: A retrospective study from a tertiary centre. Asian Journal of Urology, 2023, 10(2): 177-181.

链接本文:

http://www.ajurology.com/CN/10.1016/j.ajur.2021.10.003 或 http://www.ajurology.com/CN/Y2023/V10/I2/177

[1]	Lowrance WT, Thompson RH, Yee DS, Kaag M, Donat SM, Russo P. Obesity is associated with a higher risk of clear-cell renal cell carcinoma than with other histologies. BJU Int 2010; 105:16-20. doi: 10.1111/j.1464-410X.2009.08706.x pmid: 19583732
[2]	Kidney cancer in Australia statistics [updated 5 August 2020], https://www.canceraustralia.gov.au/affected-cancer/cancer-types/kidney-cancer/statistics. [Accessed 20 August 2020].
[3]	Lucas SM, Stern JM, Adibi M, Zeltser IS, Cadeddu JA, Raj GV. Renal function outcomes in patients treated for renal masses smaller than 4 cm by ablative and extirpative techniques. J Urol 2008; 179:75-80. doi: 10.1016/j.juro.2007.08.156 pmid: 17997440
[4]	Huang WC, Levey AS, Serio AM, Snyder M, Vickers AJ, Raj GV, et al. Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 2006; 7:735-40. doi: 10.1016/S1470-2045(06)70803-8 pmid: 16945768
[5]	Zhong J, Wah TM. Renal ablation: current management stra-tegies and controversies. Chin Clin Oncol 2019; 8:63. https://doi.org/10.21037/cco.2019.12.08. doi: 10.21037/cco.2019.12.08 pmid: 31968983
[6]	Pantelidou M, Challacombe B, McGrath A, Brown M, Ilyas S, Katsanos K, et al. Percutaneous radiofrequency ablation versus robotic-assisted partial nephrectomy for the treatment of small renal cell carcinoma. Cardiovasc Intervent Radiol 2016; 39:1595-603. doi: 10.1007/s00270-016-1417-z pmid: 27435582
[7]	Olweny EO, Park SK, Tan YK, Best SL, Trimmer C, Cadeddu JA. Radiofrequency ablation versus partial nephrectomy in pa-tients with solitary clinical T1a renal cell carcinoma: compa-rable oncologic outcomes at a minimum of 5 years of follow-up. Eur Urol 2012; 61:1156-61. doi: 10.1016/j.eururo.2012.01.001
[8]	Whitson JM, Harris CR, Meng MV. Population-based compara-tive effectiveness of nephron-sparing surgery vs. ablation for small renal masses. BJU Int 2012; 110:1438-43. doi: 10.1111/j.1464-410X.2012.11113.x pmid: 22639860
[9]	Iannuccilli JD, Dupuy DE, Beland MD, Machan JT, Golijanin DJ, Mayo-Smith WW. Effectiveness and safety of computed tomography-guided radiofrequency ablation of renal cancer: a 14-year single institution experience in 203 patients. Eur Radiol 2016; 26:1656-64. doi: 10.1007/s00330-015-4006-7 pmid: 26373755
[10]	Kim SD, Yoon SGGT. Radiofrequency ablation of renal tumors: four-year follow-up results in 47 patients. Korean J Radiol 2012; 13:625-33. doi: 10.3348/kjr.2012.13.5.625 pmid: 22977331
[11]	Tekgul S, Dogan HS, Kocvara R, Nijman JM, Radmayr C, Stein R, et al. EAU Pediatric Urology Guidelines. https://uroweb.org/guideline/paediatric-urology/. [Accessed 2 December 2017].
[12]	Carbonara U, Simone G, Capitanio U, Minervini A, Fiori C, Larcher A, et al. Robot-assisted partial nephrectomy: 7-year outcomes. Minerva Urol Nefrol 2021; 73:540-3.
[13]	Zlotta AR, Wildschutz T, Raviv G, Peny MO, van Gansbeke D, Noel JC, et al. Radiofrequency interstitial tumor ablation (RITA) is a possible new modality for treatment of renal cancer: ex vivo and in vivo experience. J Endourol 1997; 11: 251-8. doi: 10.1089/end.1997.11.251 pmid: 9376843
[14]	Mylona S, Kokkinaki A, Pomoni M, Galani P, Ntai S, Thanos L. Percutaneous radiofrequency ablation of renal cell carcinomas in patients with solitary kidney: 6 years experience. Eur J Radiol 2009; 69:351-6. doi: 10.1016/j.ejrad.2007.10.004 pmid: 18313248
[15]	Gervais DA, McGovern FJ, Arellano RS, McDougal WS, Mueller PR. Radiofrequency ablation of renal cell carcinoma: part 1, indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR Am J Roentgenol 2005; 185:64-71. doi: 10.2214/ajr.185.1.01850064
[16]	Watkins TW, Parkinson R. Percutaneous radiofrequency abla-tion of renal tumours: case series of 11 tumours and review of published work. Australas Radiol 2007; 51:412-9. pmid: 17803791
[17]	Salas N, Ramanathan R, Dummett S, Leveillee RJ. Results of radiofrequency kidney tumor ablation: renal function preservation and oncologic efficacy. World J Urol 2010; 28: 583-91. doi: 10.1007/s00345-010-0562-2 pmid: 20454965
[18]	Park S, Anderson JK, Matsumoto ED, Lotan Y, Josephs S, Cadeddu JA. Radiofrequency ablation of renal tumors: intermediate-term results. J Endourol 2006; 20:569-73. pmid: 16903817
[19]	Zagoria RJ, Traver MA, Werle DM, Perini M, Hayasaka S, Clark PE. Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. AJR Am J Roentgenol 2007; 189:429-36. doi: 10.2214/AJR.07.2258
[20]	Raman JD, Stern JM, Zeltser I, Kabbani W, Cadeddu JA. Absence of viable renal carcinoma in biopsies performed more than 1 year following radio frequency ablation confirms reli-ability of axial imaging. J Urol 2008; 179:2142-5. doi: 10.1016/j.juro.2008.01.119 pmid: 18423723
[21]	Ahrar K, Matin S, Wood CG, Wallace MJ, Gupta S, Madoff DC, et al. Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes. J Vasc Intervent Radiol 2005; 16:679-88. doi: 10.1097/01.RVI.0000153589.10908.5F
[22]	Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009; 250: 187-96. doi: 10.1097/SLA.0b013e3181b13ca2 pmid: 19638912
[23]	Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of asurvey. Ann Surg 2004; 240:205-13. doi: 10.1097/01.sla.0000133083.54934.ae

No related articles found!

[1]	Allen C. Gao,James L. Mohler. In honor of Dr. Donald S. Coffey - Prostate cancer biology and therapy[J]. Asian Journal of Urology, 2019, 6(1): 1 -2 .
[2]	Karen S. Sfanos,Srinivasan Yegnasubramanian,William G. Nelson,Tamara L. Lotan,Ibrahim Kulac,Jessica L. Hicks,Qizhi Zheng,Charles J. Bieberich,Michael C. Haffner,Angelo M. De Marzo. If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease[J]. Asian Journal of Urology, 2019, 6(1): 10 -25 .
[3]	Pei Zhao,Yezi Zhu,Liang Cheng,Jun Luo. Detection of androgen receptor (AR) and AR-V7 in small cell prostate carcinoma: Diagnostic and therapeutic implications[J]. Asian Journal of Urology, 2019, 6(1): 109 -113 .
[4]	Liqun Zhou,Kaiwei Yang,Xuesong Li,Yi Ding,Dawei Mu,Hanzhong Li,Yong Yan,Jinyi Li,Dongwen Wang,Wei Li,Yulong Cong,Jiangping Gao,Kewei Ma,Yajun Xiao,Sheng Zhang,Hongyi Jiang,Weilie Hu,Qiang Wei,Xunbo Jin,Zhichen Guan,Qingyong Liu,Danfeng Xu,Xin Gao,Yongguang Jiang,Weimin Gan,Guang Sun,Qing Wang,Yanhui Liu,Jianquan Hou,Liping Xie,Xishuang Song,Fengshuo Jin,Jiafu Feng,Ming Cai,Zhaozhao Liang,Jie Zhang,Dingwei Ye,Lin Qi,Lulin Ma,Jianzhong Shou,Yuping Dai,Jianyong Shao,Ye Tian,Shizhe Hong,Tao Xu,Chuize Kong,Zefeng Kang,Yuexin Liu,Xun Qu,Benkang Shi,Shaobin Zheng,Yi Lin,Shujie Xia,Dong Wei,Jianbo Wu,Weiling Fu,Zhiping Wang,Jianbo Liang. Application of fluorescence in situ hybridization in the detection of bladder transitional-cell carcinoma: A multi-center clinical study based on Chinese population^☆(☆ Hospitals 1 and 3w53 were all in the study group of Fluorescence in situ hybridization in prenatal genetic diseases and cancer detection in clinical research of Chinese population.)[J]. Asian Journal of Urology, 2019, 6(1): 114 -121 .
[5]	Liang Dong,Richard C. Zieren,Wei Xue,Theo M. de Reijke,Kenneth J. Pienta. Metastatic prostate cancer remains incurable, why?[J]. Asian Journal of Urology, 2019, 6(1): 26 -41 .
[6]	William B. Isaacs,Jianfeng Xu. Current progress and questions in germline genetics of prostate cancer[J]. Asian Journal of Urology, 2019, 6(1): 3 -9 .
[7]	Cameron M. Armstrong,Allen C. Gao. Current strategies for targeting the activity of androgen receptor variants[J]. Asian Journal of Urology, 2019, 6(1): 42 -49 .
[8]	Michael V. Fiandalo,Daniel T. Gewirth,James L. Mohler. Potential impact of combined inhibition of 3α-oxidoreductases and 5α-reductases on prostate cancer[J]. Asian Journal of Urology, 2019, 6(1): 50 -56 .
[9]	Tyler Etheridge,Shivashankar Damodaran,Adam Schultz,Kyle A. Richards,Joseph Gawdzik,Bing Yang,Vincent Cryns,David F. Jarrard. Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier[J]. Asian Journal of Urology, 2019, 6(1): 57 -64 .
[10]	Gina Chia-Yi Chu,Leland W.K. Chung,Murali Gururajan,Chia-Ling Hsieh,Sajni Josson,Srinivas Nandana,Shian-Ying Sung,Ruoxiang Wang,Jason Boyang Wu,Haiyen E. Zhau. Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics[J]. Asian Journal of Urology, 2019, 6(1): 65 -81 .

Viewed

Full text

Abstract

Cited

Shared

Discussed